Health Payer Intelligence September 9, 2019
– With its newly consolidated company, Cigna and Express Scripts are diving into the costly field of gene therapy and intend to increase members’ access through their new program, Embarc Benefit Protection.
“Expensive therapies for rare diseases pose a new challenge for America’s healthcare system, and this challenge will grow as more therapies are approved by the FDA,” Steve Miller, MD, Cigna’s executive vice president and chief clinical officer said in a press release. “We are leveraging our collective capabilities to deliver on the true promise of modern medicine. No cure should be out of reach of any patient, and they should receive the best quality care.”
The cost of gene therapies is escalating year by year....
Today's Sponsors
Today's Sponsor